Covid

Basic Information

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. (Source: https://www.who.int/health-topics/coronavirus#tab=tab_1)

Market Information

For vaccine - Global market size is essentially the entire worldwide population. Unanswered question is whether vaccines will need to be readministered every 1-3 years or whether there will be lifetime immunity.


For therapeutic - See HERE for coronavirus infection numbers/data.

Currently Approved Drugs 

1) Remdesivir/VEKLURY (FDA approval Oct 2020) [cite and/or link to http://investors.gilead.com/news-releases/news-release-details/us-food-and-drug-administration-approves-gileads-antiviral]

Veklury is approved for people at least 12 years old and weighing at least 88 pounds (40 kilograms) who are hospitalized for a coronavirus infection.

COST: Gilead charges $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries, and $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors. (source: https://medicalxpress.com/news/2020-10-fda-covid-drug-antiviral-remdesivir.html and https://www.livescience.com/remdesivir-fda-approved-covid19-drug.html)


2) Dexamethasone (WHO treatment Guidelines) [Jake, link to this: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1) and (https://jamanetwork.com/journals/jama/fullarticle/2770279?guestAccessKey=ec87204d-c42d-4d34-bef5-077a40bc86b0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090220)

COST: Less than $1/day (source: https://www.livescience.com/remdesivir-fda-approved-covid19-drug.html)

Image 1 

Chart

Image 2 

Chart

Current Catalysts in AMP Databases

PLRX

PLN-74809 (Dual selective inhibitor of aVβ6/aVβ1)

COVID-19

Phase 2 Data

RIGL

TAVALISSE® (fostamatinib disodium hexahydrate)

COVID-19

Phase 2 (Data)

RIGL

TAVALISSE® (fostamatinib disodium hexahydrate)

COVID-19

Phase 3 (Initiation)

Q4 2020

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon